2016, VANISH Trial – Ventricular Tachycardia Ablation versus Escalation of Antiarrhythmic Drugs, NEJM VANISH Trial Key Points: Patients with ischemic cardiomyopathy and LVEF < 35% are candidated for ICD implantation but high VT burden in these patients is associated with higher mortality despite ICD placement. Previously, antiarrhythmic therapy (AAT) specifically amiodarone has been used to..

Read more